Dr. Rao on Testing for Somatic and Germline Mutations

Video

Jianyu Rao, MD, professor and chief of Cytopathology, University of California, Los Angeles, discusses testing for somatic and germline mutations in patients with ovarian cancer.

Jianyu Rao, MD, professor and chief of Cytopathology, University of California, Los Angeles, discusses testing for somatic and germline mutations in patients with ovarian cancer.

Rao says that when a patient is diagnosed with ovarian cancer, clinicians often follow a set of algorithms to help approach genetic testing. For example, a group from Johns Hopkins Medicine has developed an algorithm to simultaneously analyze proteins and genes together with the hope of improving early detection. This technique is still relatively new, and physicians are still waiting for evidence as to whether it is clinically useful in this population.

He adds that with a better understanding of BRCA genes, pathologists can move forward with developing noninvasive approaches to treatment. Testing for mismatch repair deficiency is another recommendation for treatment. There are ways pathologists can improve early detection of ovarian cancer as well, Rao concludes.

Related Videos
Joseph G. Jurcic, MD
Zeynep Eroglu, MD
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD